Novel Bruton's Tyrosine Kinase (BTK) Substrates for Time-Resolved Luminescence Assays - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35653784/
Bruton's tyrosine kinase (BTK) is a well-documented target for cancer therapeutics due to its role in B-cell signaling pathways. However, inhibitor design is hindered by lack of tools to assess...
Relevance: Bruton's tyrosine kinase (BTK) is a well-documented target for cancer therapeutics due to its role in B-cell signaling pathways. However, inhibitor design is hindered by lack of tools to assess kinase activity.
Zanubrutinib in lymphoproliferative disorders: a comprehensive review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35651781/
Zanubrutinib is a drug that was shown to effectively treat cancer of B cells without causing excessive serious side effects Patients with certain B-cell malignancies (cancers of white blood cells)...
Conclusion: Zanubrutinib is a drug that was shown to effectively treat cancer of B cells without causing excessive serious side effects.
Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35639855/
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib irreversibly binds BTK at Cys 481 , inhibiting its kinase activity and thus blocking transduction of B cell receptor (BCR) signaling. Although ibrutinib...
Relevance: Here, we characterized the mechanism by which two BTK mutations, C481F and C481Y, may lead to ibrutinib resistance.
Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases - Annals of Hematology
Source : https://link.springer.com/article/10.1007/s00277-022-04866-z
COVID-19 in patients with hematological diseases is associated with a high mortality. Moreover, preventive vaccination demonstrated reduced efficacy and the knowledge on influencing factors is limited. In this single-center study,...
Conclusion: Rituximab and BTK inhibitor treatment were correlated significantly with a negative vaccination response, whereas younger age and chronic myeloid leukemia (CML) disease were associated with positive response. In addition, 5 of 6 patients with myeloproliferative neoplasm (MPN) and negative vaccination response were on active treatment...
BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35597428/
BTK inhibitors (BTKi) have dramatically improved outcomes for patients with chronic lymphocytic leukaemia (CLL) and some forms of B-cell lymphoma. However, new strategies are needed to enhance responses. Here we...
Conclusion: BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.